Brian Schell
Analyst · Oppenheimer.
Yes, and I would -- I want to remind folks that when we kind of came into the year, and it's a continuation of last year is the organic investments that we're making to set up the potential for this organic growth, with respect to the incremental investments we're making around, the ability to deliver DnA and data through the cloud, what we've done around enabling greater trading environment with 24/5, Tuesday, Thursday launch, the incremental marketing and branding, the Nanos launch, EU derivatives and a lot of those we've talked about. And that investment is, again, you're starting to see that payoff, both in terms of people and the marketing and the sales, and what we're doing. Specifically about, the DnA element and what you’ve asked about right is, is again, we're continuing to see that stickiness, the quality of the access, the quality of the market data that we're getting and being able to offer, again, across all asset classes, it's not just in one, obviously there's higher contribution within the derivatives franchise given the size and our placement there. But again, the confidence in continuing to deliver that growth. You'll see the forecast is slightly lower as far as the outlook than in the first half. We are going against higher comps from last year. We had great third, fourth -- third quarter and fourth quarter growth rates in DnA last year. Again, we're still confident in our continued growth. Again, the comparison is a little bit hard, but we are up for the challenge. But as far as those initiatives, right, we talked about distribution as a service, you saw the recent announcement around Morningstar and being able to leverage our existing networks. We're excited about packaging or global content, again, across geographies and asset classes. And then John had mentioned earlier, again, is that organic opportunity just within say, for example, within Australia and Japan and our recent entry there and within Canada, so those items are really continued, again, give us confidence about the growth rate as we head into the rest of this year. And then obviously, conviction around the medium to longer term growth opportunity of DnA.